Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients

Withdrawn before enrolling · Phase 4

Conditions studied: Renal Failure

In brief

Ceftazidime is a broad spectrum cephalosporin with high activity against a variety of Gram-negative pathogens, including Pseudomonas aeruginosa. An open-label study of intravenous ceftazidime pharmacokinetics will be performed in patients undergoing intermittent hemodialysis at Northwestern Memorial Hospital to determine the clearance of ceftazidime in high flux hemodialysis.

Key facts

Study ID

NCT01507532

Run by

Midwestern University

People needed

0

Starts

2012-01-01

Expected to finish

2016-01-01

Last updated by the study team

2018-03-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eligible patients are male or female adults ≥18 years of age with an expected hospital stay of at least 48 hours, who have end-stage renal disease and been receiving intermittent hemodialysis for at least 90 days.
• Eligible patients will additionally have either central or peripheral intravenous access, and will already be prescribed ceftazidime per their primary providers.
• Written informed consent in a form approved by Northwestern Memorial Hospital, Northwestern University Institutional Review Board, and Midwestern University Institutional Review Board will be completed by the patient prior to enrollment.

You may not qualify if…

• Patients that only receive one dose of ceftazidime in total
• Patients with potentially altered pharmacokinetic parameters (pregnant patients, burn patients, and those that are morbidly obese (BMI ≥ 40 kg/m2).
• Not meeting inclusion criteria

Where it is running

• Northwestern Memorial Hospital — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.